Arixa Pharmaceuticals' Seed - II Round

Arixa Pharmaceuticals raised a round of funding on May 01, 2018.

Arixa Pharmaceuticals is developing oral antibiotics for resistant gram-negative infections. Its lead program is an oral prodrug of Avibactam, a broad spectrum beta-lactamase inhibitor. It has address…

Articles about Arixa Pharmaceuticals' Seed - II Round: